Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul-Sep;47(3):103861.
doi: 10.1016/j.htct.2025.103861. Epub 2025 Jun 16.

CD36 as a marker of acute myeloid leukemia prognosis: A systematic review

Marina Chaves Amantéa  1 , Rafaela Pires da Silva  1 , Larissa Ranini Soares  1 , João Lorenzo de Medeiros Pereira  1 , Ana Paula Duarte de Souza  2
Affiliations
Review

CD36 as a marker of acute myeloid leukemia prognosis: A systematic review

Marina Chaves Amantéa et al. Hematol Transfus Cell Ther. 2025 Jul-Sep.

Abstract

CD36 is a glycoprotein associated with resistance to chemotherapy and the recurrence of acute myeloid leukemia. This systematic review aims to evaluate the impact of CD36 on the prognosis of acute myeloid leukemia, a complex heterogeneous malignant hematopoietic disease. The Embase, Scopus, Web of Science, Cochrane Library and SciELO databases were searched until September 2023. Only studies that analyzed CD36 expression in humans were included. Of 905 articles identified from the databases, 600 were screened and nine were included. The Newcastle-Ottawa Scale was used to evaluate the methodological quality of the studies. According to this systematic review, CD36 is associated with different prognostic factors in acute myeloid leukemia, including remission and relapse of the disease, overall survival, and chemoresistance.

Keywords: Acute myeloid leukemia; Antigen; Cd36; Prognosis; Prognostic factors.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flow diagram of study selection process.
See this image and copyright information in PMC

References

    1. Seth R., Singh A. Leukemias in children. Ind J Pediatr. 2015;82(9):817–824. doi: 10.1007/s12098-015-1695-5. - DOI - PubMed
    1. Gao C., Li X., Xu Y., Zhang T., Zhu H., Yao D. Recent advances in CAR-T cell therapy for acute myeloid leukaemia. J Cell Mol Med. 2024;28(9) doi: 10.1111/jcmm.18369. - DOI - PMC - PubMed
    1. Zhou J., Chng W.J. Unveiling novel insights in acute myeloid leukemia through single-cell RNA sequencing. Front Oncol. 2024;14 doi: 10.3389/fonc.2024.1365330. - DOI - PMC - PubMed
    1. National Cancer Institute; USA: 2021. SEER Cancer Statistics Review, 1975-2018 [Internet]https://seer.cancer.gov/csr/1975_2018/ Available from.
    1. Sakamoto K.M., Grant S., Saleiro D., Crispino J.D., Hijiya N., Giles F., et al. Targeting novel signaling pathways for resistant acute myeloid leukemia. Mol Genet Metab. 2015;114(3):397–402. doi: 10.1016/j.ymgme.2014.11.017. - DOI - PMC - PubMed

LinkOut - more resources